Product Code: 1922
The esoteric testing market is anticipated to showcase robust growth through 2028 primarily on account of surging product demand among consumers in key regions across the globe. Additionally, latest developments in the technology, along with rising incidences of chronic illnesses, are set to further bolster industry expansion over the forecast period.
Industry players have been implementing effective strategies to gain a competitive edge in the market, which has positively influenced business growth. For instance, in February 2021, Mayo Clinic Laboratories, the U.S.-based medical laboratory, inked a partnership agreement with SRL Diagnostics, an Indian diagnostics expert, with the objective of promoting research, co-hosting seminars, training, conferences, and symposia around esoteric tests.
To cite another instance, in June 2021, ARUP Laboratories, a national reference laboratory under Utah University and a non-profit enterprise specializing in esoteric assays, announced the opening of its new laboratory facility in Salt Lake City, Utah. The novel structure spans two buildings and is a first-of-its-kind facility that has been designed to improve efficiency and boost test turnaround times. As a result, growing presence of diagnostic laboratories in leading regions has played a vital role in the growth of the esoteric testing industry in recent years.
For comprehensive assessment, the esoteric testing market has been categorized on the basis of technology, test type, and region. Based on test type, the market has been segregated further into infectious disease & immunology, endocrinology, toxicology, oncology, genomics, neurology, and others.
The genomics sub-segment garnered a substantial valuation in 2021 and is slated to grow at more than 6.9% CAGR between 2022 and 2028. Notable advancements in the sequencing technologies, including NGS, and surging awareness regarding the early detection of genetic disorders are likely to stimulate segmental growth in the forthcoming years.
From the technology perspective, the esoteric testing market has been divided into flow cytometry, ELISA, mass spectrometry, chemiluminescence, RT-PCR, radioimmunoassay, and others. In 2021, the mass spectrometry sub-segment was valued at over USD 4.0 billion and is projected to observe sizable growth through the assessment period. Increasing R&D investments towards clinical testing, coupled with technological breakthroughs in mass spectrometers, is anticipated to accelerate segmental development in the coming years.
In the regional landscape, the Latin America esoteric testing market accounted for a significant portion of the overall industry revenue in 2021 and is estimated to attain a considerable revenue, growing at a CAGR of approximately 7.1% between 2022 and 2028. Increasing healthcare spending, rising awareness about rare and complex disorders, and prevalent expansion of specialty labs are poised to foster regional market outlook in the future.
Table of Contents
Chapter 1 Methodology
- 1.1 Market definitions
- 1.2 Base estimates & working
- 1.2.1 North America
- 1.2.2 Europe
- 1.2.3 Asia Pacific
- 1.2.4 Latin America
- 1.2.5 Middle East & Africa
- 1.3 Forecast parameters
- 1.4 Data validation
- 1.5 Data Sources
- 1.5.1 Secondary
- 1.5.1.1 Paid sources
- 1.5.1.2 Unpaid sources
- 1.5.2 Primary
Chapter 2 Executive Summary
- 2.1 Esoteric testing industry 360 degree synopsis, 2017 - 2028
- 2.1.1 Business trends
- 2.1.2 Test type trends
- 2.1.3 Technology trends
- 2.1.4 Regional trends
Chapter 3 Esoteric Testing Industry Insights
- 3.1 Industry segmentation
- 3.2 Industry landscape, 2017 - 2028
- 3.3 Industry impact forces
- 3.3.1 Growth drivers
- 3.3.1.1 Technological advancements in esoteric testing
- 3.3.1.2 Rising occurrence of complex and rare medical disorders in the U and Europe
- 3.3.1.3 Increasing prevalence of cancer and infectious diseases in low and middle-income countries
- 3.3.1.4 Growing demand for genomics and proteomics
- 3.3.1.5 Rising awareness for early disease detection across the globe
- 3.3.2 Industry pitfalls & challenges
- 3.3.2.1 Dearth of qualified and trained professionals in developing countries
- 3.3.2.2 Stringent regulatory framework
- 3.4 Growth potential analysis
- 3.4.1 By test type
- 3.4.2 By technology
- 3.5 COVID 19 impact analysis
- 3.6 Types of business models
- 3.6.1 Mobile lab services
- 3.6.2 Full-service diagnostics
- 3.6.3 Reference/ consulting Services
- 3.7 Regulatory landscape
- 3.7.1 U.S.
- 3.7.2 Europe
- 3.7.3 China
- 3.8 Porter's analysis
- 3.9 Competitive landscape, 2021
- 3.10 PESTEL analysis
Chapter 4 Esoteric Testing Market, By Test Type
- 4.1 Key segment trends
- 4.2 Endocrinology
- 4.2.1 Market estimates and forecast, by region, 2017 - 2028
- 4.3 Infectious disease & immunology
- 4.3.1 Market estimates and forecast, by region, 2017 - 2028
- 4.4 Oncology
- 4.4.1 Market estimates and forecast, by region, 2017 - 2028
- 4.5 Toxicology
- 4.5.1 Market estimates and forecast, by region, 2017 - 2028
- 4.6 Neurology
- 4.6.1 Market estimates and forecast, by region, 2017 - 2028
- 4.7 Genomics
- 4.7.1 Market estimates and forecast, by region, 2017 - 2028
- 4.8 Others
- 4.8.1 Market estimates and forecast, by region, 2017 - 2028
Chapter 5 Esoteric Testing Market, By Technology
- 5.1 Key segment trends
- 5.2 Mass spectrometry
- 5.2.1 Market estimates and forecast, by region, 2017 - 2028
- 5.3 Flow cytometry
- 5.3.1 Market estimates and forecast, by region, 2017 - 2028
- 5.4 ELISA
- 5.4.1 Market estimates and forecast, by region, 2017 - 2028
- 5.5 Radioimmunoassay
- 5.5.1 Market estimates and forecast, by region, 2017 - 2028
- 5.6 Chemiluminescence
- 5.6.1 Market estimates and forecast, by region, 2017 - 2028
- 5.7 RT-PCR
- 5.7.1 Market estimates and forecast, by region, 2017 - 2028
- 5.8 Others
- 5.8.1 Market estimates and forecast, by region, 2017 - 2028
Chapter 6 Esoteric Testing Market, By Region
- 6.1 Key regional trends
- 6.2 North America
- 6.2.1 Market estimates and forecast, by country, 2017 - 2028
- 6.2.2 Market estimates and forecast, by test type, 2017 - 2028
- 6.2.3 Market estimates and forecast, by technology, 2017 - 2028
- 6.2.4 U.S.
- 6.2.4.1 Market estimates and forecast, by test type, 2017 - 2028
- 6.2.4.2 Market estimates and forecast, by technology, 2017 - 2028
- 6.2.5 Canada
- 6.2.5.1 Market estimates and forecast, by test type, 2017 - 2028
- 6.2.5.2 Market estimates and forecast, by technology, 2017 - 2028
- 6.3 Europe
- 6.3.1 Market estimates and forecast, by country, 2017 - 2028
- 6.3.2 Market estimates and forecast, by test type, 2017 - 2028
- 6.3.3 Market estimates and forecast, by technology, 2017 - 2028
- 6.3.4 UK
- 6.3.4.1 Market estimates and forecast, by test type, 2017 - 2028
- 6.3.4.2 Market estimates and forecast, by technology, 2017 - 2028
- 6.3.5 Germany
- 6.3.5.1 Market estimates and forecast, by test type, 2017 - 2028
- 6.3.5.2 Market estimates and forecast, by technology, 2017 - 2028
- 6.3.6 France
- 6.3.6.1 Market estimates and forecast, by test type, 2017 - 2028
- 6.3.6.2 Market estimates and forecast, by technology, 2017 - 2028
- 6.3.7 Italy
- 6.3.7.1 Market estimates and forecast, by test type, 2017 - 2028
- 6.3.7.2 Market estimates and forecast, by technology, 2017 - 2028
- 6.3.8 Spain
- 6.3.8.1 Market estimates and forecast, by test type, 2017 - 2028
- 6.3.8.2 Market estimates and forecast, by technology, 2017 - 2028
- 6.4 Asia Pacific
- 6.4.1 Market estimates and forecast, by country, 2017 - 2028
- 6.4.2 Market estimates and forecast, by test type, 2017 - 2028
- 6.4.3 Market estimates and forecast, by technology, 2017 - 2028
- 6.4.4 Japan
- 6.4.4.1 Market estimates and forecast, by test type, 2017 - 2028
- 6.4.4.2 Market estimates and forecast, by technology, 2017 - 2028
- 6.4.5 China
- 6.4.5.1 Market estimates and forecast, by test type, 2017 - 2028
- 6.4.5.2 Market estimates and forecast, by technology, 2017 - 2028
- 6.4.6 India
- 6.4.6.1 Market estimates and forecast, by test type e, 2017 - 2028
- 6.4.6.2 Market estimates and forecast, by technology, 2017 - 2028
- 6.4.7 South Korea
- 6.4.7.1 Market estimates and forecast, by test type, 2017 - 2028
- 6.4.7.2 Market estimates and forecast, by technology, 2017 - 2028
- 6.5 Latin America
- 6.5.1 Market estimates and forecast, by country, 2017 - 2028
- 6.5.2 Market estimates and forecast, by test type, 2017 - 2028
- 6.5.3 Market estimates and forecast, by technology, 2017 - 2028
- 6.5.4 Brazil
- 6.5.4.1 Market estimates and forecast, by test type, 2017 - 2028
- 6.5.4.2 Market estimates and forecast, by technology, 2017 - 2028
- 6.5.5 Mexico
- 6.5.5.1 Market estimates and forecast, by test type, 2017 - 2028
- 6.5.5.2 Market estimates and forecast, by technology, 2017 - 2028
- 6.6 Middle East & Africa
- 6.6.1 Market estimates and forecast, by country, 2017 - 2028
- 6.6.2 Market estimates and forecast, by test type, 2017 - 2028
- 6.6.3 Market estimates and forecast, by technology, 2017 - 2028
- 6.6.4 South Africa
- 6.6.4.1 Market estimates and forecast, by test type, 2017 - 2028
- 6.6.4.2 Market estimates and forecast, by technology, 2017 - 2028
- 6.6.5 Saudi Arabia
- 6.6.5.1 Market estimates and forecast, by test type, 2017 - 2028
- 6.6.5.2 Market estimates and forecast, by technology, 2017 - 2028
- 6.6.6 UAE
- 6.6.6.1 Market estimates and forecast, by test type, 2017 - 2028
- 6.6.6.2 Market estimates and forecast, by technology, 2017 - 2028
Chapter 7 Company Profiles
- 7.1 Competitive dashboard, 2021
- 7.2 ACM Global Laboratories
- 7.2.1 Business overview
- 7.2.2 Financial data
- 7.2.3 Product landscape
- 7.2.4 Strategic outlook
- 7.2.5 SWOT analysis
- 7.3 American Esoteric Laboratories (AEL)
- 7.3.1 Business overview
- 7.3.2 Financial data
- 7.3.3 Product landscape
- 7.3.4 Strategic outlook
- 7.3.5 SWOT analysis
- 7.4 Arup Laboratories
- 7.4.1 Business overview
- 7.4.2 Financial data
- 7.4.3 Product landscape
- 7.4.4 Strategic outlook
- 7.4.5 SWOT analysis
- 7.5 BioMONTR
- 7.5.1 Business overview
- 7.5.2 Financial data
- 7.5.3 Product landscape
- 7.5.4 Strategic outlook
- 7.5.5 SWOT analysis
- 7.6 Fulgent Genetics Inc
- 7.6.1 Business overview
- 7.6.2 Financial data
- 7.6.3 Product landscape
- 7.6.4 Strategic outlook
- 7.6.5 SWOT analysis
- 7.7 Genomic Health
- 7.7.1 Business overview
- 7.7.2 Financial data
- 7.7.3 Product landscape
- 7.7.4 Strategic outlook
- 7.7.5 SWOT analysis
- 7.8 Invitae
- 7.8.1 Business overview
- 7.8.2 Financial data
- 7.8.3 Product landscape
- 7.8.4 Strategic outlook
- 7.8.5 SWOT analysis
- 7.9 Laboratory Corporation of America
- 7.9.1 Business overview
- 7.9.2 Financial data
- 7.9.3 Product landscape
- 7.9.4 Strategic outlook
- 7.9.5 SWOT analysis
- 7.10 Mayo Medical Laboratories
- 7.10.1 Business overview
- 7.10.2 Financial data
- 7.10.3 Product landscape
- 7.10.4 Strategic outlook
- 7.10.5 SWOT analysis
- 7.11 Miraca Holdings Inc.
- 7.11.1 Business overview
- 7.11.2 Financial data
- 7.11.3 Product landscape
- 7.11.4 Strategic outlook
- 7.11.5 SWOT analysis
- 7.12 Myriad Genetics
- 7.12.1 Business overview
- 7.12.2 Financial data
- 7.12.3 Product landscape
- 7.12.4 Strategic outlook
- 7.12.5 SWOT analysis
- 7.13 Nordic Laboratories
- 7.13.1 Business overview
- 7.13.2 Financial data
- 7.13.3 Product landscape
- 7.13.4 Strategic outlook
- 7.13.5 SWOT analysis
- 7.14 OPKO Health Inc.
- 7.14.1 Business overview
- 7.14.2 Financial data
- 7.14.3 Product landscape
- 7.14.4 Strategic outlook
- 7.14.5 SWOT analysis
- 7.15 Quest Diagnostics, Inc.
- 7.15.1 Business overview
- 7.15.2 Financial data
- 7.15.3 Product landscape
- 7.15.4 Strategic outlook
- 7.15.5 SWOT analysis